ArticleNature communications2023
The Trypanosoma cruzi Antigen and Epitope Atlas: antibody specificities in Chagas disease patients across the Americas.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 29 citations in OpenAlex.
- Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay.Nature communications · 2024Trial
- Reconstructing pathogen-specific antibody binding epitopes and age-dependent immune signatures from proteomic-scale peptide libraries.Science advances · 2026Article
- Evaluation of a Novel Peptide-Based ELISA for the Serological Diagnosis of Trypanosoma cruzi Infection.Clinical and translational science · 2026Article
- Article
- Epitope mapping and conservation of antigens from the Multi-Cruzi immunoassay platform.Medical microbiology and immunology · 2026Article
- A Trypanosoma cruzi trans-sialidase peptide demonstrates high serological prevalence among infected populations across endemic regions.The Journal of clinical investigation · 2026Article
- Conjugates of α-d-Galp-(1→3)-β-d-Galp for the serological diagnosis of Chagas disease.PLoS neglected tropical diseases · 2026Article
- Software and Tools to Analyze High-Density Peptide Array Data for the Chagas Antigen and Epitope Atlas.Methods in molecular biology (Clifton, N.J.) · 2026Article
- K-mer-based approach for serodiagnostic antigen discovery in Chagas disease using unassembled sequencing reads.PLoS neglected tropical diseases · 2025Article
- Reconstructing pathogen-specific antibody binding epitopes and age-dependent immune signatures from proteomic-scale peptide libraries.medRxiv : the preprint server for health sciences · 2025Article
- The patent landscape of Chagas disease vaccines indicates major underinvestment in an emerging global health threat.Nature biotechnology · 2025Article
- Coinfection by multipleMicrobiology and molecular biology reviews : MMBR · 2025Review
- Association of antibody and T cell receptor repertoires in Trypanosoma cruzi infected rhesus macaques and host response to infection.Journal of biomedical science · 2025Article
- Phospholipids and phospholipase A1 as antigens during the course of experimental Trypanosoma cruzi infection.Memorias do Instituto Oswaldo Cruz · 2025Article
- Diagnosis of Trypanosoma cruzi infection in Mexican populations: current conventional serology lacks adequate sensitivity and specificity.Memorias do Instituto Oswaldo Cruz · 2025Article
- Identification of highly conservedEmerging microbes & infections · 2024Article
- Prevalence ofTropical medicine and infectious disease · 2024Article
- Diversity of Chagas disease diagnostic antigens: Successes and limitations.PLoS neglected tropical diseases · 2024Review
- A Multi-Epitope Protein for High-Performance Serodiagnosis of Chronic Chagas Disease in ELISA and Lateral Flow Platforms.International journal of molecular sciences · 2024Article
- The epidemiology of Chagas disease in the Americas.Lancet regional health. Americas · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 11 institutions in 6 countries.
Funding
Abstract
During an infection the immune system produces pathogen-specific antibodies. These antibody repertoires become specific to the history of infections and represent a rich source of diagnostic markers. However, the specificities of these antibodies are mostly unknown. Here, using high-density peptide arrays we examined the human antibody repertoires of Chagas disease patients. Chagas disease is a neglected disease caused by Trypanosoma cruzi, a protozoan parasite that evades immune mediated elimination and mounts long-lasting chronic infections. We describe a proteome-wide search for antigens, characterised their linear epitopes, and show their reactivity on 71 individuals from diverse human populations. Using single-residue mutagenesis we revealed the core functional residues for 232 of these epitopes. Finally, we show the diagnostic performance of identified antigens on challenging samples. These datasets enable the study of the Chagas antibody repertoire at an unprecedented depth and granularity, while also providing a rich source of serological biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.